| Literature DB >> 32994136 |
Nobuhiro Asai1, Daisuke Sakanashi2, Wataru Ohashi3, Akiko Nakamura2, Atsuko Yamada2, Yuzuka Kawamoto2, Narimi Miyazaki2, Tomoko Ohno2, Isao Koita2, Hiroyuki Suematsu2, Takaaki Kishino4, Hideo Kato5, Mao Hagihara6, Arufumi Shiota1, Yusuke Koizumi1, Yuka Yamagishi1, Hiroshige Mikamo7.
Abstract
The novel coronavirus disease 2019 (COVID-19) is diagnosed by positive result of reverse transcription polymerase chain reaction (RT-PCR) for the novel coronavirus. We concluded that cycle threshold value (Ct-value) of real-time RT-PCR (rRT-PCR) assay could decrease as patients recover. Results of rRT-PCR assay could remain positive among asymptomatic patients for longer than 2 weeks. The discharge criteria of COVID-19 patients using a negative result of rRT-PCR should be reconsidered.Entities:
Keywords: COVID-19; Coronavirus; RT-PCR; SARS-CoV-2; Wuhan
Mesh:
Substances:
Year: 2020 PMID: 32994136 PMCID: PMC7480734 DOI: 10.1016/j.jiac.2020.09.010
Source DB: PubMed Journal: J Infect Chemother ISSN: 1341-321X Impact factor: 2.211
Patients’ characteristics and clinical outcomes (Ct-value and disease severity).
| Cases | Age | Sex | Past history | Initial | Re-checked | Pneumonia | Duration of admission (days) | ICU admission | Treatment | Outcome |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 56 | M | Hypertension | 18 | 32.2 | Yes | 17 | No | Ciclesonide, Camostat, Favipiravir | Survival |
| 2 | 55 | F | None | 22 | 22.1 | Yes | 18 | No | Ciclesonide, | Survival |
| 3 | 16 | F | None | 27 | 29.6 | Yes | 8 | No | Ciclesonide, | Survival |
| 4 | 48 | M | None | 27 | 45 | Yes | 15 | Yes | Ciclesonide, | Survival |
| 5 | 22 | M | None | 16 | 29.4 | Yes | 7 | No | Ciclesonide, Camostat, Favipiravir | Survival |
| 6 | 50 | M | DM, HTN, | 18 | 28 | Yes | 11 | No | Ciclesonide, | Survival |
| 7 | 92 | M | Dementia, | 14 | 16 | Yes | 12 | No | Favipiravir | Death |
| 8 | 25 | M | None | 22 | 24.5 | No | 14 | No | Ciclesonide, | Survival |
| 9 | 63 | F | RA | 16 | 19.6 | No | 23 | No | Favipiravir | Survival |
| 10 | 48 | F | None | 27 | 28.2 | No | 13 | No | Ciclesonide, | Survival |
Ct-value, cycle threshold value; DM, diabetes mellitus; HTN, hypertension; IIP, idiopathic interstitial pneumonia; ICU, intensive care unit; RA, rheumatoid arthritis; M, male; F, female.
The patient was treated due to the age and underlying disease.
Fig. 1Shows that Ct-values detected by RT–PCR in nasopharyngeal swabs from COVID-19 patients.
Comparison with pneumonia and non-pneumonia group among COVID-19 patients in Ct-value, re-checked Ct-value and change amount by nasopharyngeal RT-PCR.
| Variables | Pneumonia group (n = 7) | Non-pneumonia group (n = 3) | |
|---|---|---|---|
| Median age (range years) | 50 (16–92 years) | 48 (25–63 years) | NT |
| Male gender (%) | 5/2 (71) | 1/2 (33) | 0.5 |
| Initial Ct-value | 20.3 ± 5.4 | 21.7 ± 5.9 | 0.733 |
| Re-checked Ct-value | 28.9 ± 8.3 | 24.1 ± 3.5 | 0.414 |
| Change amount of Ct-value between initial and re-check | −8.6 ± 6.8 | −2.4 ± 1.6 | 0.176 |
COVID-19, novel coronavirus disease 2019; Ct-value, cycle threshold value; NT, not tested, RT-PCR, reverse transcription-polymerase chain reaction.